Hepatitis C affects a quarter of a million Australians, causing insidious but progressive liver disease which culminates in liver failure or cancer. There is no vaccine and prevention programs have limited effectiveness, but new antiviral therapies now offer high rates of cure. This Program will evaluate strategies to improve the health of those affected and prevent new infections by better understanding of the virus and the body’s immune response, including scarring and liver cancer formation.
The Elimination Of Hepatitis C As A Global Public Health Threat
Funder
National Health and Medical Research Council
Funding Amount
$7,001,475.00
Summary
In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2 ....In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2030.Read moreRead less
Improving The Health Of People With Problematic Drug Use: Hepatitis C And Drug Dependence
Funder
National Health and Medical Research Council
Funding Amount
$9,060,140.00
Summary
Problematic drug use is the major risk factor to health among Australians aged 15-49 years. The dual harms of drug dependence and hepatitis C virus (HCV) faced by people who use drugs compel improved drug dependence management and HCV prevention and treatment. This Program Grant will improve the lives of people with problematic drug use by investigating health impacts of drug use and evaluating new strategies for managing drug dependence and eliminating HCV among people who use drugs.
The development of cures, vaccines and better treatments for HIV/AIDS is an urgent global health priority. This team of seven groups in Sydney and Melbourne will study how HIV can lie dormant in some parts of the body, evading eradication by HIV therapy, as well as how the immune system responds to the virus. This will allow for design of novel vaccines and treatments. The researchers have skills in basic virology and immunology, and translating laboratory findings into human clinical trials.
Addressing The Major Challenges In HIV Vaccine And Cure Research
Funder
National Health and Medical Research Council
Funding Amount
$16,136,755.00
Summary
HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections each year. Despite advances in management of HIV infection with antiretroviral therapy, there is still no cure, no effective vaccine, and several co-infections reduce life expectancy. This program assembles Australia’s leading HIV researchers to use innovative basic and translational science to tackle priority areas in controlling the HIV epidemic.